Saccharomyces cerevisiae fungemia in a critically ill patient with acute cholangitis and long term probiotic use

Mustafa Fadhel; Swapnil Patel; Edward Liu; Michael Levitt; Arif Asif

doi:10.1016/j.mmcr.2018.11.003

Saccharomyces cerevisiae fungemia in a critically ill patient with acute cholangitis and long term probiotic use

Med Mycol Case Rep. 2018 Nov 12:23:23-25. doi: 10.1016/j.mmcr.2018.11.003. eCollection 2019 Mar.

Authors

Mustafa Fadhel¹, Swapnil Patel¹, Edward Liu¹, Michael Levitt¹, Arif Asif¹

Affiliation

¹ Department of Medicine, Jersey Shore University Medical Center, 1945 State Route 33, Neptune, NJ 07750, United States.

Abstract

Saccharomyces cerevisiae has recently been used as an ingredient in probiotic supplements. Invasive Saccharomyces infection have been documented, and multiple predisposing risk factors have been identified including critical illness, ICU admission, antibiotics use, central venous catheters, probiotics use, and immunosuppression. We report a case of a 74-year-old man admitted for acute cholangitis taking a probiotic supplement containing the subtype Saccharomyces boulardii. He later developed S. cerevisiae fungemia that was successfully treated with Micafungin and Fluconazole.

Keywords: Fungemia; Micafungin; Probiotic supplement; Saccharomyces boulardii; Saccharomyces cerevisiae.

Publication types

Case Reports